Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 9/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17494477 | 1.00 | LMNA (0.35) | LMNATRPM8ALDH1A1MEN1MAPK1 | |
| SCHEMBL9580681 | 0.69 | TRPM8 (0.37) | LMNATRPM8ALDH1A1SMN1; SMN2 | |
| SCHEMBL18929559 | 0.67 | SLC6A4 (0.35) | ALDH1A1 | |
| SCHEMBL27140352 | 0.64 | LMNA (0.42) | LMNATRPM8ALDH1A1MEN1KMT2A | |
| SCHEMBL29873769 | 0.64 | LMNA (0.50) | LMNAALDH1A1MEN1MAPK1KMT2A | |
| SCHEMBL24138156 | 0.63 | LMNA (0.47) | LMNATRPM8ALDH1A1MEN1MAPK1 | |
| SCHEMBL31138348 | 0.63 | LMNA (0.47) | LMNATRPM8ALDH1A1MEN1MAPK1 | |
| SCHEMBL29801338 | 0.61 | OPRM1 (0.39) | LMNAMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL849272 | 0.61 | TSPO (0.44) | LMNAALDH1A1MEN1MAPK1KMT2A | |
| SCHEMBL3201714 | 0.61 | GAA (0.41) | LMNAALDH1A1MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160726-B2 | Quinolone derivatives as antibacterials | NOVARTIS AG (CH) | 2018-12-25 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| EP-3177593-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | Novartis AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020836-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | TOP1, NQO2, TOP2A | LMNA 1693/4885TRPM8 4670/4885ALDH1A1 1836/4885 |
| US-10160726-B2 | Quinolone derivatives as antibacterials | TOP1, NQO2, TOP2A | LMNA 1693/4885TRPM8 4670/4885ALDH1A1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.